DrugPatentWatch Database Preview
NERLYNX Drug Profile
Which patents cover Nerlynx, and what generic alternatives are available?
Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this drug.
This drug has ninety-six patent family members in twenty countries.
The generic ingredient in NERLYNX is neratinib maleate. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.
Summary for NERLYNX
| International Patents: | 96 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 74 |
| Clinical Trials: | 2 |
| Patent Applications: | 111 |
| Drug Prices: | Drug price information for NERLYNX |
| DailyMed Link: | NERLYNX at DailyMed |
Generic Entry Opportunity Date for NERLYNX
Generic Entry Date for NERLYNX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for NERLYNX
International Patents for NERLYNX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Australia | 2010316683 | ➤ Try a Free Trial |
| Russian Federation | 2463300 | ➤ Try a Free Trial |
| World Intellectual Property Organization (WIPO) | 2010117633 | ➤ Try a Free Trial |
| European Patent Office | 2258698 | ➤ Try a Free Trial |
| World Intellectual Property Organization (WIPO) | 2011055303 | ➤ Try a Free Trial |
| Japan | 2015044871 | ➤ Try a Free Trial |
| South Korea | 20180041753 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
